Wanshi Medical Secures RMB 100 Million Series A Funding and Receives China's First NMPA Approval for Neurovascular Interventional Robotic System

Recently,Beijing Wansi Medical Technology Co., Ltd. (“Wansi Medical”) announced the completion of its RMB 100 million angel financing round, co-led by Guoke Investment and Nuoyu Capital, with Zero2IPO Capital serving as the exclusive long-term financial advisor.The proceeds from this funding round will be allocated to R&D, new product iteration, team development, and market promotion.

Wansi Medical is dedicated to the research, development, and industrialization of robotic systems for vascular interventional procedures. The company was founded under the leadership of Professor Li Youxiang, a neurointerventional expert at Beijing Tiantan Hospital, Capital Medical University (hereinafter referred to as “Tiantan Hospital”). Originating from clinical practice and stemming from a key national R&D project supported by the Ministry of Science and Technology of China, the company has now achieved successful commercial deployment. Its flagship product, the vascular interventional surgical robot, is the first such device in China to enter clinical trials, having completed multi-center clinical studies nationwide ahead of its peers, and has obtainedChina’s First NMPA Registration Certificate for “Cerebrovascular Interventional Surgery Assistance Operating System” (Robot), with its product development now at the forefront internationally, it may be the first to break through in the rapidly growing market segment of vascular interventional robotics.

The vascular intervention market, represented by neurovascular interventions, has a strong demand for surgical robots. Stroke has a high mortality rate and affects a large patient population, while surgical procedures are fraught with pain points and technical challenges. Surgical robots can significantly improve operational efficiency and reduce surgical risks through high-precision, intelligent manipulation.

Stroke is an acute cerebrovascular disease characterized by a group of conditions that cause brain tissue damage due to sudden rupture of cerebral blood vessels or blockage preventing blood flow to the brain. It ranks first in both mortality and disability rates in China, with the number of patients increasing at an annual rate of 9%. From 2016 to 2030, the number of new stroke cases is projected to rise by 118 million.

Compared with pharmacological and surgical treatments, interventional therapy boasts unique advantages, including minimal invasiveness, rapid postoperative recovery, fewer complications, and a broad range of indications, making it highly regarded in clinical practice. However, the penetration rate of interventional therapy remains low in China. This is primarily due to several challenges that hinder the rapid development of neurointerventional procedures: the fine and tortuous nature of cerebral vessels, their thin and fragile walls, the high technical difficulty and intensity of neurointerventional surgeries, significant radiation exposure, prolonged learning curves for physicians, and shortened career spans. Furthermore, there is a scarcity of specialists in the field of neurointervention, leaving patients in remote and rural areas unable to receive timely treatment. From 2024 to 2030, the market size of neurointerventional surgical robots in China is projected to grow at a compound annual growth rate (CAGR) of 40%.

As a pioneer in vascular interventional surgical robots in China, Vansi Medical has continuously innovated from the perspectives of clinicians and patients, addressing clinical pain points to develop interventional robotic products that are truly practical, user-friendly, and preferred in clinical practice. The company’s interventional surgical robot enables remote operation from outside the procedure room and covers the entire workflow of vascular interventional surgeries. It thoroughly liberates physicians from high-radiation environments, eliminating the need to wear heavy lead aprons and allowing them to perform procedures in optimal condition. Meanwhile, the robot extends surgeons’ movements with millimeter-level precision, significantly enhancing the safety, stability, and accuracy of surgical operations, ultimately benefiting patients.

Wansi Medical has entered the market through neurointervention, selecting angiography—the most prevalent procedure in neurovascular interventional therapy—as the clinical focus for its first-generation product, thereby addressing the most immediate clinical application needs. Meanwhile, its operation encompasses all fundamental movements involved in vascular interventional surgery: catheter and guidewire delivery and rotation. It can simulate physicians’ actions of holding, delivering, and rotating catheters and guidewires, laying the robotic operational foundation for all vascular interventional procedures and building an “aircraft carrier”-level platform solution for future pan-vascular interventional robotics. In the future, these robots will be capable of AI-based assessment, preoperative planning, and intraoperative alerts, enabling safer and more effective patient treatment. Additionally, 5G and intelligent technologies will empower primary healthcare institutions.

In 2017, to advance the development of the vascular interventional surgical robotics industry, the Ministry of Science and Technology included “Industrialization and Demonstration Application Research of High-Precision Minimally Invasive Vascular Interventional Surgical Robots” in its National Key R&D Program, with the project undertaken and led by Professor Li Youxiang’s team at Beijing Tiantan Hospital. In 2018, Yidu Hebei Robotics Technology Co., Ltd. (hereinafter referred to as “Yidu Medical”) was established to facilitate the commercialization and implementation of the project. The company set up a manufacturing facility with a comprehensive quality management system compliant with ISO 13485 for medical devices. Subsequently, Beijing Wansi Medical was founded, and Yidu Medical was incorporated as its subsidiary.

In 2021, Wansi Medical took the lead in completing a nationwide, multi-center clinical trial involving 260 cases, with participation from Beijing Chaoyang Hospital Affiliated to Capital Medical University, the First Hospital of Hebei Medical University, and Shanxi Provincial People's Hospital. In 2022, the Ministry of Science and Technology’s project “Industrialization and Demonstration Application of High-Precision Minimally Invasive Vascular Intervention Surgical Robots” was successfully concluded, passing the major project evaluation and review by the Ministry of Science and Technology. In March 2023, Wansi Medical’s “Cerebrovascular Intervention Surgery Assistance Operating System” received approval for market launch from the National Medical Products Administration (NMPA).This is China's first NMPA registration certificate for an "Assisted Operating System for Cerebrovascular Interventional Surgery" (robot).。

The company’s robotic products have been successfully shortlisted for the Ministry of Industry and Information Technology’s “Open Competition” program for AI-enabled medical device innovation, selected as a key demonstration project under the Ministry of Education’s “Capital Medical Innovation Project,” and honored with multiple awards in the medical device category at leading international competitions, including the Excellence Award at the China Disruptive Technology Innovation Competition. Vans Medical has achieved significant breakthroughs in the clinical adoption, commercialization, and industrialization of minimally invasive vascular interventional surgical robots. In the development of these robots, the company has realized independent innovation in multiple key technologies, positioning its robotic products at the forefront of global advancement.

Wansi Medical boasts a clinical expert team from Tiantan Hospital, an engineering R&D team with industrial backgrounds such as GE, and a marketing, sales, and operational management team. The close collaboration and efficient operation between the medical and engineering teams enable the robots to better understand clinical practices, thereby developing vascular interventional robot products that truly meet clinical needs.

The clinical team comprises medical experts from Beijing Tiantan Hospital, leveraging their extensive clinical experience to empower robotic R&D. Professor Li Youxiang, the founder, serves as the Chief Expert of the Neurointerventional Center at Beijing Tiantan Hospital, Director of the Beijing Neurointerventional Engineering Center, and Leader of the Interventional Group under the Neurosurgery Branch of the Chinese Medical Association. With over 30 years of experience in neurointervention, he brings profound expertise to the field. The frontline clinical team possesses a deep understanding of clinical pain points. By addressing the most practical clinical issues based on the actual characteristics of vascular interventional procedures, they ensure that R&D outcomes fully align with clinical needs, thereby enhancing product usability and stability.

The engineering team comprises R&D experts with industrial backgrounds from companies such as GE, leveraging mature and advanced R&D systems and product lifecycle management expertise. This ensures quality throughout the entire process—from clinical need identification and product requirement definition to risk management, solution design, and validation—thereby enabling rapid product development, iteration, and regulatory certification.

The company’s management and operations team possesses advanced management and sales marketing expertise from Fortune 500 enterprises such as GE, and has accumulated extensive experience and resources in the successful operation of startups. Furthermore, the team has substantial resources in market sales, management and operations, branding, and distribution channels for medical device products, which are expected to safeguard the company’s efficient operations and market sales performance.

It is reported that Vans Medical will continue to strengthen its R&D and independent innovation, exploring cutting-edge technologies such as multimodal image data fusion navigation and AI-based automatic path planning. Meanwhile, the company will launch the surgical simulation cabin VAS COACH, which fully simulates robotic operation scenarios during surgery to train physicians and cultivate talent for the industry. Starting with neurointervention, Vans Medical is building an ecosystem for vascular interventional procedures, promoting the industrialization of vascular interventions, and continuously creating new value for human health and well-being.

Professor Li Youxiang, Founder of Wansi Medicalstated: “This financing will continue to support Vansi Medical in focusing on clinically valuable, innovative solutions for vascular intervention. In fact, medical device R&D cannot be driven solely by a ‘technology-first’ mindset; clinical needs and applications are fundamental. This is the core driving force behind Vansi’s leading development in the field of vascular interventional surgical robotics. We extend our gratitude to Guoke Investment and Nuoyu Capital for their recognition and investment in Vansi Medical, and to Zero2IPO Capital for providing professional financial advisory services. Following the completion of this funding round, Vansi Medical will continue to uphold a pragmatic and innovative spirit, accelerate product iteration, gradually expand the range of clinically applicable procedures, continuously empower physicians, and benefit patients.”

Li Jin, Chief Operating Officer of Wansi MedicalHe stated, “China has nearly 300 million patients with cardiovascular and cerebrovascular diseases. Interventional surgery has become the preferred treatment option, and the digitalization, precision, and intelligentization of vascular interventions represent an inevitable trend. Wansi Medical is committed to transforming clinical needs in the field of vascular intervention into robotic precision therapy solutions. The company has obtained China’s first registration certificate for a vascular interventional surgical robot (surgical assistance device), marking a solid step in Wansi Medical’s commercialization strategy and laying a strong foundation for future robot-based intelligent surgical navigation systems and surgical simulation training platforms. We extend our gratitude to Guoke Investment and Nuoyu Capital for their encouragement and trust, as well as to Zero2IPO Capital for their support. Wansi Medical will continue to advance steadily, providing globally leading robotic solutions for vascular interventional surgeries to physicians and patients.”

Li Haomin, Chief Technology Officer at Vans Medicalstated: “Vance Medical boasts a professional team integrating expertise in clinical practice, marketing, scientific research, and engineering, backed by profound industry experience. With the support of financing, we will be better positioned to strengthen our interdisciplinary talent pool. Moving forward, we will continuously optimize our existing products based on clinical feedback, providing users with precise, reliable, and user-friendly interventional surgical assistance systems. Furthermore, we will initiate new product development projects to expand clinical applications for emerging surgical procedures. In line with our product launch roadmap, we will increase investment in advanced technology research to ensure sustained momentum for future new product development.”

Principal Investigator of the Multicenter Clinical Trial, Director Wang Yang, Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical UniversityHe stated, “Given the inherent challenges of neurointerventional procedures—including high technical difficulty, prolonged duration, and significant risks—clinicians have long anticipated the ability to perform precise surgeries on patients in a radiation-free and weight-bearing-free environment. This is now achievable with robotic assistance. Our team is honored to participate in China’s first clinical trial of a vascular interventional surgical robot. Compared with traditional interventional techniques that rely heavily on operator experience, robotic systems offer superior precision control and enable quantifiable operations. This enhances procedural safety and efficiency for physicians, while substantially shortening the learning curve. In the future, it will also simplify and facilitate physician training.”

Liu Chunguang, Investment Director at Guoke Investment“It is believed that ‘Wansi Medical is a pioneer in the vascular interventional surgical robotics industry. Starting from genuine clinical needs, the company has targeted the field of stroke treatment, which is characterized by high mortality rates and significant surgical complexity. It has broken through multiple core technologies for the clinical application of neurovascular interventional robots, achieved industrialization ahead of its peers, and taken a leading position in the industry. In the future, the company’s products will expand into other therapeutic areas, such as coronary and peripheral vascular interventions. We look forward to the company’s team continuously iterating and developing new products to serve clinical practice and create greater value.’”

Yang Zhiwen, Managing Partner at Nuoyu Capital Management“It is believed that interventional radiologists work in radiation environments and must wear heavy lead aprons, lead glasses, and lead collars, yet they remain unable to avoid long-term occupational hazards. Excessive fatigue among physicians leads to diminished physical stamina and concentration, inadvertently significantly increasing surgical risks for patients. The interventional medicine sector has long anticipated a new technology that would enable physicians to work in a safe and comfortable environment, delivering more precise, efficient, and stable surgical procedures to the benefit of both patients and clinicians. We are pleased to see that Vans Medical has taken the lead in providing this solution and has become the first company in China to obtain an NMPA registration certificate in this field. We believe the Vans team will continue to bring more surprising products to the market in the future.”

Sun Zengping, Partner at Zero2IPO Capitalstated: “Wansi Medical’s vascular interventional surgical robot is born from clinical practice, applied in clinical settings, and dedicated to benefiting clinical outcomes, truly empowering clinicians comprehensively and improving patient care. Wansi Medical has achieved remarkable speed—‘Wansi Speed’—in clinical integration, product development, and commercialization. We are confident that it will accelerate the high-quality development of the vascular intervention industry. Qingke Capital is honored to serve as the exclusive financing advisor and long-term partner of Wansi Medical, collaborating efficiently with the Wansi team to witness and participate in its innovative growth.”

Beijing Wansi Medical Technology Co., Ltd. (hereinafter referred to as “Wansi Medical”) is a leading enterprise in China’s vascular interventional robotics industry, focusing on the research and development, manufacturing, and services of vascular interventional surgical robots and their consumables. The company is dedicated to transforming clinical needs in the field of vascular intervention into precise robotic therapeutic solutions. Wansi Medical and its controlling subsidiary, Yidu Hebei Robotics Technology Co., Ltd. (hereinafter referred to as “Yidu Medical”), were founded under the leadership of Professor Li Youxiang, a neuro-interventional expert at Beijing Tiantan Hospital affiliated with Capital Medical University. As the commercialization entity for a key national R&D project supported by the Ministry of Science and Technology, the company independently developed the “Cerebrovascular Interventional Surgical Assistance Operating System” (robot), which is the first vascular interventional surgical robot approved for market launch by the National Medical Products Administration (NMPA) in China. Starting with neurovascular interventional therapy, Wansi Medical is building an ecosystem for vascular interventional surgery, helping to elevate the standard of vascular interventional medical care, continuously empowering physicians, and benefiting patients.

Guoke Investment is a professional investment management company controlled by CAS Holdings Co., Ltd., with participation from the State-owned Assets Supervision and Administration Commission of the State Council and an employee stock ownership company.

Guoke Investment was honored with the titles of “Top 30 Best Venture Capital Firms in China for 2022” and “Top 10 Private Equity Firms with the Best Returns from 2017 to 2022” by Financing China; “Top 37 Best Venture Capital Investors in China for 2021” and “Top 30 Best Investors in Advanced Manufacturing Industry” by China Venture; “Top 35 Private Equity Firms in China for 2022” by Zero2IPO; and “Top 10 Fund Managers with the Most Consistent Top-Tier Performance in Greater China” by Preqin.

Guoke Investment has invested in leading enterprises across niche sectors such as innovative drugs, minimally invasive interventions, precision diagnosis and treatment, and surgical intelligence, facilitating their rapid growth.

Noyu Capital is an early-stage venture capital fund founded by investors with extensive experience in the healthcare industry. With a long-term focus on medical devices and digital health, the firm prioritizes early-stage investment opportunities and is dedicated to identifying entrepreneurs who can genuinely address healthcare challenges through a long-term perspective.

The core members of the Nuoyu Investment team each possess over 10 years of experience in the healthcare industry, with profound expertise in medical diagnostic and therapeutic technologies and a deep understanding of business operating models. They provide startups with the most critical growth support needed in areas such as early-stage project evaluation and post-investment value creation. The firm has established comprehensive coverage across numerous tracks within the medical device and digital health sectors, including brain science, cardiovascular and cerebrovascular diseases, surgical robotics, and medical AI. Key portfolio companies include Huihe Medical, Changmugu, Vivace, Tingsheng Technology, and Qianglian Zhichuang.

Zero2IPO Ventures (1945.HK) established Zero2IPO Capital in 2000. As one of China’s leading new-generation boutique investment banks, it focuses on serving innovative enterprises with high growth potential in the new economy. The firm has successfully assisted companies and investment institutions in completing hundreds of private equity financing, mergers and acquisitions, IPOs, PIPE transactions, and privatizations, covering all stages of corporate development. We are committed to providing professional and efficient financing solutions to founders and entrepreneurs, helping them and investors achieve greater business success. Zero2IPO Capital primarily serves sectors such as healthcare, advanced manufacturing, artificial intelligence, and enterprise services. Within healthcare, its team specifically focuses on opportunities in sub-sectors including medical devices and IVD, innovative drugs and advanced therapies, innovative medical services, and digital health.